GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity

Experimental Cell Research

Volumn 323, Issue 1, 2014, Pages 100-111

  Fiorentini, Chiara ^a   Bodei, Serena ^a   Bedussi, Francesca ^a   Fragni, Martina ^a   Bonini, Sara Anna ^a   Simeone, Claudio ^a   Zani, Danilo ^a,b   Berruti, Alfredo ^a   Missale, Cristina ^a   Memo, Maurizio ^a   Spano, PierFranco ^a   Sigala, Sandra ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Istituto Clinico Città di Brescia Hospital   (Italy)

Author keywords

Apoptosis; GPNMB osteoactivin; Invasivity; Metalloproteinases; Prostate cancer

Indexed keywords

GELATINASE A; GELATINASE B; GLYCOPROTEIN; GLYCOPROTEIN MELANOMA PROTEIN B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR INVASION; UPREGULATION;

APOPTOSIS; GPNMB/OSTEOACTIVIN; INVASIVITY; METALLOPROTEINASES; PROSTATE CANCER;

APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MEMBRANE GLYCOPROTEINS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84896494492     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2014.02.025     Document Type: Article

References (81)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics. CA: Cancer J. Clin. 2009, 59:225-249.
2. Mouraviev V., Mayes J.M., Polascik T.J. Pathologic basis of focal therapy for early-stage prostate cancer. Nat. Rev. Urol. 2009, 6:205-215.
3. Nelson P.S. Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J. Clin. Oncol. 2012, 30:644-646.
4. Zivi A., Massard C., De-Bono J. Changing therapeutic paradigms in castrate-resistant prostate cancer. Clin. Genitourin.Cancer 2010, 8:17-22.
5. Garraway L.A., Sellers W.R. Lineage dependency and lineage-survival oncogenes in human cancer. Nat. Rev. Cancer 2006, 6:593-602.
6. Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate 2000, 42:150-160.
7. Montano X., Djamgoz M.B. Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer. FEBS Lett. 2004, 571:1-8.
8. Arrighi N., Bodei S., Zani D., Simeone C., Cunico S.C., Missale C., Spano P.F., Sigala S. Nerve growth factor signaling in prostate health and disease. Growth Factors 2010, 28:191-201.
9. Sigala S., Faraoni I., Botticini D., Paez-Pereda M., Missale C., Bonmassar E., Spano P.F. Suppression of telomerase, reexpression of KAI1, and abrogation of tumorigenicity by nerve growth factor in prostate cancer cell lines. Clin. Cancer Res. 1999, 5:1211-1218.
10. Sigala S., Tognazzi N., Rizzetti M.C., Faraoni I., Missale C., Bonmassar E., Spano P.F. Nerve growth factor induces the re-expression of functional androgen receptors and p75 (NGFR) in the androgen-insensitive prostate cancer cell line DU145. Eur. J. Endocrinol. 2002, 147:407-415.
11. Sigala S., Bodei S., Missale C., Zani D., Simeone C., Cunico S.C., Spano P.F. Gene expression profile of prostate cancer cell lines: effect of nerve growth factor treatment. Mol. Cell. Endocrinol. 2008, 284:11-20.
12. Safadi F.F., Xu J., Smock S.L., Rico M.C., Owen T.A., Popoff S.N. Cloning and characterization of osteoactivin, a novel cDNA expressed in osteoblasts. J. Cell. Biochem. 2001, 84:12-26.
13. Singh M., Del Carpio-Cano F., Belcher J.Y., Crawford K., Frara N., Owen T.A., Popoff S.N., Safadi F.F. Functional roles of osteoactivin in normal and disease processes. Crit. Rev. Eukaryot. Gene Expr. 2010, 20:341-357.
14. Williams M.D., Esmaeli B., Soheili A., Simantov R., Gombos D.S., Bedikian A.Y., Hwu P. GPNMB expression in uveal melanoma: a potential for targeted therapy. Melanoma Res. 2010, 20:184-190.
15. Tse K.F., Jeffers M., Pollack V.A., McCabe D.A., Shadish M.L., Khramtsov N.V., Hackett C.S., Shenoy S.G., Kuang B., Boldog F.L., MacDougall J.R., Rastelli L., Herrmann J., Gallo M., Gazit-Bornstein G., Senter P.D., Meyer D.L., Lichenstein H.S., LaRochelle W.J. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin. Cancer Res. 2006, 12:1373-1382.
16. Onaga M., Ido A., Hasuike S., Uto H., Moriuchi A., Nagata K., Hori T., Hayash K., Tsubouchi H. Osteoactivin expressed during cirrhosis development in rats fed a choline-deficient, l-amino acid-defined diet, accelerates motility of hepatoma cells. J. Hephatol. 2003, 39:779-785.
17. Rich J.N., Shi Q., Hjelmeland M., Cummings T.J., Kuan C.T., Bigner D.D., Counter C.M., Wang X.F. Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. J. Biol. Chem. 2003, 278:15951-15957.
18. Kuan C.T., Wakiya K., Dowell J.M., Herndon J.E., Reardon D.A., Graner M.W., Riggins G.J., Wikstrand C.J., Bigner D.D. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clin. Cancer Res. 2006, 12:1970-1982.
19. Rose A.A., Pepin F., Russo C., Abou Khalil J.E., Hallett M., Siegel P.M. Osteoactivin promotes breast cancer metastasis to bone. Mol. Cancer Res. 2007, 5:1001-1014.
20. Rose A.A., Grosset A.A., Dong Z., Russo C., Macdonald P.A., Bertos N.R., St-Pierre Y., Simantov R., Hallett M., Park M., Gaboury L., Siegel P.M. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin. Cancer Res. 2010, 16:2147-2156.
21. Rose A.A., Annis M.G., Dong Z., Pepin F., Hallett M., Park M., Siegel P.M. ADAM10 releases a soluble form of the OA/osteoactivin extracellular domain with angiogenic properties. PLOS One 2010, 5:e12093.
22. Xiao Y.B., Qiao Z.G., Zhang X.W., Liu Z.H., Xie J., Hao Y.C., Yu W.D., Xu T., Wang X.F. Expression of glycoprotein non-metastatic melanoma protein B in prostate cancer and its significance. Beijing Da Xue Xue Bao 2011, 43:496-499.
23. Tsui K.H., Chang Y.L., Feng T.H., Chang P.L., Juang H.H. Glycoprotein transmembrane nmb: an androgen-downregulated gene attenuates cell invasion and tumorigenesis in prostate carcinoma cells. Prostate 2012, 72:1431-1442.
24. Lokeshwar B.L. MMP inhibition in prostate cancer. Ann. N. Y. Acad. Sci. 1999, 878:271-289.
25. Nemeth J.A., Yousif R., Herzog M., Che M., Upadhyay J., Shekarriz B., Bhagat S., Mullins C., Fridman R., Cher M.L. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J. Nat. Cancer Inst. 2002, 94:17-25.
26. Reis S.T., Pontes-Junior J., Antunes A.A., de Sousa-Canavez J.M., Dall[U+05F3]Oglio M.F., Passerotti C.C., Abe D.K., Crippa A., da Cruz J.A., Timoszczuk L.M., Srougi M., Leite K.R. MMP-9 overexpression due to TIMP-1 and RECK underexpression is associated with prognosis in prostate cancer. Int. J. Biol. Markers 2011, 26:255-261.
27. Aalinkeel R., Nair B.B., Reynolds J.L., Sykes D.E., Mahajan S.D., Chadha K.C., Schwartz S.A. Overexpression of MMP-9 contributes to invasiveness of prostate cancer cell line LNCaP. Immunol. Investig. 2011, 40:447-464.
28. Mironova E.V., Evstratova A.A., Antonov S.M. A fluorescence vital assay for the recognition and quantification of excitotoxic cell death by necrosis and apoptosis using confocal microscopy on neurons in culture. J. Neurosci. Methods 2007, 163:1-8.
29. Abdelmagid S.M., Barbe M.F., Rico M.C., Salihoglu S., Arango-Hisijara I., Selim A.H., Anderson M.G., Owen T.A., Popoff S.N., Safadi F.F. Osteoactivin, an anabolic factor that regulates osteoblast differentiation and function. Exp. Cell Res. 2008, 314:2334-2351.
30. Selim A.A., Abdelmagid S.M., Kanaan R.A., Smock S.L., Owen T.A., Popoff S.N., Safadi F.F. Anti-osteoactivin antibody inhibits osteoblast differentiation and function in vitro. Crit. Rev. Eukaryot. Gene Expr. 2003, 13:265-275.
31. Furochi H., Tamura S., Mameoka M., Yamada C., Ogawa T., Hirasaka K., Okumura Y., Imagawa T., Oguri S., Ishidoh K., Kishi K., Higashiyama S., Nikawa T. Osteoactivin fragments produced by ectodomain shedding induce MMP-3 expression via ERK pathway in mouse NIH-3T3 fibroblasts. FEBS Lett. 2007, 581:5743-5750.
32. Jones J.L., Walker R.A. Control of matrix metalloproteinase activity in cancer. J. Pathol. 1997, 183:377-379.
33. Murphy G. Tissue inhibitors of metalloproteinases. Genome Biol. 2011, 12:233-240.
34. Tan C.T., Chu C.Y., Lu Y.C., Chang C.C., Lin B.R., Wu H.H., Liu H.L., Cha S.T., Prakash E., Ko J.Y., Kuo M.L. CXCL12/CXCR4 promotes laryngeal and hypopharyngeal squamous cell carcinoma metastasis through MMP-13-dependent invasion via the ERK1/2/AP-1 pathway. Carcinogenesis 2008, 29:1519-1527.
35. Babykutty S., P.P.S., N.R.J., Kumar M.A., Nair M.S., Srinivas P., Gopala S. Nimbolide retards tumor cell migration, invasion, and angiogenesis by downregulating MMP-2/9 expression via inhibiting ERK1/2 and reducing DNA-binding activity of NF-κB in colon cancer cells. Mol. Carcinog. 2012, 51:475-490.
36. Borczuk A.C., Gorenstein L., Walter K.L., Assaad A.A., Wang L., Powell C.A. Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am. J. Pathol. 2003, 163:1949-1960.
37. Nielsen T.O., West R.B., Linn S.C., Alter O., Knowling M.A., O[U+05F3]Connell J.X., Zhu S., Fero M., Sherlock G., Pollack J.R., Brown P.O., Botstein D., van de Rijn M. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002, 359:1301-1307.
38. Weterman M.A., Ajubi N., van Dinter I.M., Degen W.G., van Muijen G.N., Ruitter D.J., Bloemers H.P. Nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int. J. Cancer 1995, 60:73-81.
39. Missale C., Boroni F., Losa M., Giovanelli M., Zanellato A., Dal Toso R., Balsari A., Spano P.F. Nerve growth factor suppresses the transforming phenotype of human prolactinomas. Proc. Natl. Acad. Sci. USA 1993, 90:7961-7975.
40. Páez Pereda M., Missale C., Grübler Y., Arzt E., Schaaf L., Stalla G.K. Nerve growth factor and retinoic acid inhibit proliferation and invasion in thyroid tumor cells. Mol. Cell. Endocrinol. 2000, 167:99-106.
41. Missale C., Codignola A., Sigala S., Finardi A., Paez-Pereda M., Sher E., Spano P.F. Nerve growth factor abrogates the tumorigenicity of human small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA 1998, 95:5366-5371.
42. Missale C., Losa M., Sigala S., Balsari A., Giovanelli M., Spano P.F. Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism. Mol. Endocrinol. 1996, 10:272-285.
43. Fiorentini C., Facchetti M., Finardi A., Sigala S., Páez-Pereda M., Sher E., Spano P.F., Missale C. Nerve growth factor and retinoic acid interactions in the control of small cell lung cancer proliferation. Eur. J. Endocrinol. 2002, 147:371-379.
44. Graham C.W., Lynch J.H., Djakiew D. Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. J. Urol. 1992, 147:1444-1447.
45. Perez M., Regan T., Pflug B., Lynch J., Djakiew D. Loss of low-affinity nerve growth factor receptor during malignant transformation of the human prostate. Prostate 1997, 30:274-279.
46. Pflug B., Djakiew D. Expression of p75NTR in a human prostate epithelial tumor cell line reduces nerve growth factor-induced cell growth by activation of programmed cell death. Mol. Carcinog. 1998, 23:106-114.
47. Nalbandian A., Djakiew D. The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells. Clin. Exp. Metastasis 2006, 23:107-116.
48. Nalbandian A., Pang A.L., Rennert O.M., Chan W.Y., Ravindranath N., Djakiew D. A novel function of differentiation revealed by cDNA microarray profiling of p75NTR-regulated gene expression. Differentiation 2005, 73:385-396.
49. Allen J., Khwaja F., Djakiew D. Gene therapy of prostate xenograft tumors with a p75NTR lipoplex. Anticancer Res. 2004, 24:2997-3003.
50. Allen J., Khwaja F., Byers S., Djakiew D. The p75NTR mediates a bifurcated signal transduction cascade through the NF kappa B and JNK pathways to inhibit cell survival. Exp. Cell Res. 2005, 304:69-80.
51. Carter B.D., Kaltschmidt C., Kaltschmidt B., Offenhäuser N., Böhm-Matthaei R., Baeuerle P.A., Barde Y.A. Selective activation of NF-kappa B by nerve growth factor through the neurotrophin receptor p75. Science 1996, 272:542-545.
52. Fiorentini C., Guerra N., Facchetti M., Finardi A., Tiberio L., Schiaffonati L., Spano P.F., Missale C. Nerve growth factor regulates dopamine D(2) receptor expression in prolactinoma cell lines via p75(NGFR)-mediated activation of nuclear factor-kappaB. Mol. Endocrinol. 2002, 16:353-366.
53. Driessler F., Venstrom K., Sabat R., Asadullah K., Schottelius A.J. Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin. Exp. Immunol. 2004, 135:64-73.
54. Zhong H., May M.J., Jimi E., Ghosh S. The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1. Mol. Cell 2002, 9:625-636.
55. Guan H., Hou S., Ricciardi R.P. DNA binding of repressor nuclear factor-kappaB p50/p50 depends on phosphorylation of Ser337 by the protein kinase A catalytic subunit. J. Biol. Chem. 2005, 280:9957-9962.
56. Messeguer X., Escudero R., Farré D., Nuñez O., Martínez J., Albà M. PROMO: detection of known transcription regulatory elements using species-tailored searches. Bioinformatics 2002, 18:333-334.
57. Farré D., Roset R., Huerta M., Adsuara J.E., Roselló L., Albà M., Messeguer X. Identification of patterns in biological sequences at the ALGGEN server: PROMO and MALGEN. Nucleic Acids Res. 2003, 31:3651-3653.
58. Sheng M.H., Wergedal J.E., Mohan S., Lau K.H. Osteoactivin is a novel osteoclastic protein and plays a key role in osteoclast differentiation and activity. FEBS Lett. 2008, 582(10):1451-1458.
59. Shikano S., Bonkobara M., Zukas P.K., Ariizumi K. Molecular cloning of a dendritic cell-associated transmembrane protein, DC-HIL, that promotes RGD-dependent adhesion of endothelial cells through recognition of heparan sulfate proteoglycans. J. Biol. Chem. 2001, 276(11):8125-8234.
60. Naim H.Y., Joberty G., Alfalah M., Jacob R. Temporal association of the N- and O-linked glycosylation events and their implication in the polarized sorting of intestinal brush border sucrase-isomaltase, aminopeptidase N, and dipeptidyl peptidase IV. J. Biol. Chem. 1999, 274:17961-17967.
61. Burchell J., Poulsom R., Hanby A., Whitehouse C., Cooper L., Clausen H., Miles D., Taylor-Papadimitriou J. An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology 1999, 9:1307-1311.
62. Morgia G., Falsaperla M., Malaponte G., Madonia M., Indelicato M., Travali S., Mazzarino M.C. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer. Urol. Res. 2005, 33:44-50.
63. Moses M.A., Wiederschain D., Loughlin K.R., Zurakowski D., Lamb C.C., Freeman M.R. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res. 1998, 58:1395-1399.
64. Brehmer B., Biesterfeld S., Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. Prostate Cancer Prostatic Dis. 2003, 6:217-222.
65. Wood M., Fudge K., Mohler J.L., Frost A.R., Garcia F., Wang M., Stearns M.E. In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin. Exp. Metastasis 1997, 15:246-258.
66. Trudel D., Fradet Y., Meyer F., Harel F., Têtu B. Significance of MMP-2 expression in prostate cancer: an immunohistochemical study. Cancer Res. 2003, 63:8511-8515.
67. Sanchez-Sweatman O.H., Orr F.W., Singh G. Human metastatic prostate PC3 cell lines degrade bone using matrix metalloproteinases. Invasion Metastasis 1998, 18:297-305.
68. Roomi M.W., Kalinovsky T., Rath M., Niedzwiecki A. Down-regulation of urokinase plasminogen activator and matrix metalloproteinases and up-regulation of their inhibitors by a novel nutrient mixture in human prostate cancer cell lines PC-3 and DU-145. Oncol. Rep. 2011, 26:1407-1413.
69. London C.A., Sekhon H.S., Arora V., Stein D.A., Iversen P.L., Devi G.R. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther. 2003, 10(11):823-832.
70. Nalla A.K., Gorantla B., Gondi C.S., Lakka S.S., Rao J.S., MMP-9 Targeting uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells. Cancer Gene Ther. 2010, 17(9):599-613.
71. Zhong W.D., Han Z.D., He H.C., Bi X.C., Dai Q.S., Zhu G., Ye Y.K., Liang Y.X., Qin W.J., Zhang Z., Zeng G.H., Chen Z.N. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Oncology 2008, 75:230-236.
72. Escaff S., Fernández J.M., González L.O., Suárez A., González-Reyes S., González J.M., Vizoso F.J. Study of matrix metalloproteinases and their inhibitors in prostate cancer. Br. J. Cancer 2010, 102:922-929.
73. Nonsrijun N., Mitchai J., Brown K., Leksomboon R., Tuamsuk P. Overexpression of matrix metalloproteinase 11 in thai prostatic adenocarcinoma is associated with poor survival. Asian Pac. J. Cancer Prev. 2013, 14:3331-3335.
74. Gomez D.E., Alonso D.F., Yoshiji H., Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 1997, 74:111-122.
75. Brew K., Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim. Biophys. Acta 2010, 1803:55-71.
76. Zhou L.T., Liu F.Y., Li Y., Peng Y.M., Liu Y.H., Li J. Gpnmb/osteoactivin, an attractive target in cancer immunotherapy. Neoplasma 2012, 59:1-5.
77. Tomihari M., Chung J.S., Akiyoshi H., Cruz P.D., Ariizumi K. DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells. Cancer Res. 2010, 70:5778-5787.
78. Qian X., Mills E., Torgov M., LaRochelle W.J., Jeffers M. Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate. Mol. Oncol. 2008, 2:81-93.
79. Pollack V.A., Alvarez E., Tse K.F., Torgov M.Y., Xie S., Shenoy S.G., MacDougall J.R., Arrol S., Zhong H., Gerwien R.W., Hahne W.F., Senter P.D., Jeffers M.E., Lichenstein H.S., LaRochelle W.J. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting OA. Cancer Chemother. Pharmacol. 2007, 60:423-435.
80. Naumovski L., Junutula J.R. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr. Opin. Mol. Ther. 2010, 12:248-257.
81. Keir C.H., Vahdat L.T. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer. Expert Opin. Biol. Ther. 2012, 12:259-263.